SPORADIC INCLUSION BODY MYOSITIS (SIBM)

Clinical trials for SPORADIC INCLUSION BODY MYOSITIS (SIBM) explained in plain language.

Never miss a new study

Get alerted when new SPORADIC INCLUSION BODY MYOSITIS (SIBM) trials appear

Sign up with your email to follow new studies for SPORADIC INCLUSION BODY MYOSITIS (SIBM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Early trial tests new drug duo for rare Muscle-Wasting disease

Disease control Recruiting now

This is a small, early-stage pilot study testing whether a combination of two drugs, pozelimab and cemdisiran, can help control the progression of sporadic inclusion body myositis (sIBM), a rare muscle-wasting disease. Ten participants will receive injections every four weeks for…

Matched conditions: SPORADIC INCLUSION BODY MYOSITIS (SIBM)

Phase: EARLY_PHASE1 • Sponsor: Austin Neuromuscular Center • Aim: Disease control

Last updated Mar 25, 2026 14:07 UTC

SPORADIC INCLUSION BODY MYOSITIS (SIBM)

Get alerted when new SPORADIC INCLUSION BODY MYOSITIS (SIBM) trials appear

Early trial tests new drug duo for rare Muscle-Wasting disease